T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
25 10월 2023 - 5:05AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid
detection of sepsis-causing pathogens and antibiotic resistance
genes, today highlighted four new studies supporting the
T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel
that were recently presented at the IDWeek conference in Boston,
Massachusetts. The data demonstrates the speed, accuracy and
clinical benefits of the T2Dx® Instrument and T2 Biosystems’ sepsis
panels and early analytical data on the T2Resistance Panel.
“We are encouraged by our latest clinical
results as they showcase the critical detection capabilities of
both our instrument and sepsis test panels. Adding to our clinical
data library and increasing awareness of the clinical and economic
benefits of our technology is an important part of our commercial
strategy," said John Sperzel, Chairman and CEO of T2 Biosystems.
“In addition, we appreciate the strong display of support from our
customers as they continue to highlight real world performance and
benefits of our sepsis products in their sepsis patient
management.”
Data Highlights
Acting on Results: How Culture
Independent Diagnostics Impact Patient Care and
Stewardship Audry Hawkins, PharmD, BCIDP, University of
Louisville (UofL) Health System and Navaneeth Narayanan, PharmD,
MPH, BCIDP, Robert Wood Johnson Hospital
Speakers reviewed the implementation of
T2Bacteria and T2Candida, clinical impacts and case studies:
- Reviewed patient selection criteria
for T2Bacteria at UofL Health System and shared 3 clinical cases
where T2Bacteria facilitated faster optimization of antimicrobial
therapy and provided clarity in the setting of negative cultures in
highly antimicrobial experienced patients.
- Reviewed T2Candida patient criteria
and algorithms for responding to T2Candida results at Robert Wood
Johnson Hospital and shared 2 clinical cases where T2Candida
facilitated appropriate source evaluation and control in a
critically ill patient in the setting of a positive result and
facilitated de-escalation of antifungals in the setting of a
negative result.
Candidemia: Role of T2Candida® compared
to Bact/Alert Virtuo blood culture system in a real-world
setting Birk NK et al., Henry Ford Hospital
The poster presentation found that T2Candida
continues to outperform at detecting candidemia blood culture even
as blood culture monitoring technology advances.
- Retrospective study comparing all
patients with T2Candida and blood culture results collected from
January 2018 to January 2019 (VersaTREK; n=522) and March 2019 to
March 2020 (Virtuo; n=348) comparing the positivity rate of
T2Candida and the two respective blood culture monitoring systems.
Positivity rates were significantly higher with T2Candida (8.6%)
compared to blood culture (2.7%) in the VersaTREK cohort,
p<0.001. Positivity rates were significantly higher with
T2Candida (9.8%) compared to blood culture (2.3%) in the Virtuo
cohort, p<0.001.
Predictors of 30-Day Mortality Among Critically Ill
Patients with Candidemia Identified by T2Candida Panel
Caniff KE et al., Anti-infective Research Laboratory/Wayne State
University
Poster on retrospective, multi-center study
evaluating predictors of 30-day mortality in patients with known
T2Candida positive results including the following conclusions:
- “Empiric antifungal administration and ID consultation are
modifiable risk factors that were independently associated with
reduced odds of 30-day mortality in patients with candidemia
identified by T2Candida Panel, highlighting their importance in
clinical management”
- “Real-world use of the T2Candida Panel allowed for rapid
identification of candidemia and prompt initiation of definitive
therapy”
Rapid Detection of Antibiotic Resistance Genes Direct
from Whole Blood Samples by T2 Magnetic Resonance (T2MR®)
Wang J et al., T2Biosystems
T2 Biosystems authored poster on analytical
studies evaluating the limit of detection, analytical
reactivity/inclusivity, interfering substances, and analytical
specificity/exclusivity of the T2Resistance Panel.
- Limit of detection for all 13 genes
was <20 CFU/mL (ranging from 3-18 CFU/mL).
- The panel has broad inclusivity of
resistance gene variants, no observed interfering substances from
those tested, and no observed cross-reactivity with other species
or resistance markers.
About T2 BiosystemsT2
Biosystems, a leader in the rapid detection of sepsis-causing
pathogens and antibiotic resistance genes, is dedicated to
improving patient care and reducing the cost of care by helping
clinicians effectively treat patients faster than ever before. T2
Biosystems’ products include the T2Dx® Instrument, the T2Bacteria®
Panel, the T2Candida® Panel, the T2Resistance® Panel, the
T2Biothreat™ Panel, and the T2SARS-CoV-2™ Panel and are powered by
the proprietary T2 Magnetic Resonance (T2MR®) technology. T2
Biosystems has an active pipeline of future products, including the
Acinetobacter baumannii test, the Candida auris test, and the
T2Lyme™ Panel, as well as next-generation products for the
detection of bacterial and fungal pathogens and associated
antimicrobial resistance markers. For more information, please
visit www.t2biosystems.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding the
detection capabilities of the Company’s T2Dx Instrument and sepsis
test panels, the clinical and economic benefits of the Company’s
technology, and the real world performance and benefits of the
Company’s sepsis products , as well as statements that include the
words “expect,” “may,” “should,” “anticipate,” and similar
statements of a future or forward-looking nature. These
forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to make
or obtain anticipated FDA filings or clearances within expected
time frames or at all; or (iv) the factors discussed under Item 1A.
“Risk Factors” in the Company’s Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the U.S. Securities and
Exchange Commission, or SEC, on March 31, 2023, and other filings
the Company makes with the SEC from time to time, including our
Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.
These and other important factors could cause actual results to
differ materially from those indicated by the forward-looking
statements made in this press release. Any such forward-looking
statements represent management’s estimates as of the date of this
press release. While the Company may elect to update such
forward-looking statements at some point in the future, unless
required by law, it disclaims any obligation to do so, even if
subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the Company’s views as of any
date subsequent to the date of this press release.
Investor Contact:Philip Trip Taylor, Gilmartin
Groupir@T2Biosystems.com 415-937-5406
T2 Biosystems (NASDAQ:TTOO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
T2 Biosystems (NASDAQ:TTOO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024